inato | CASE STUDY

Phase III Metastatic Breast Cancer Trial

Study Basics

- **Disease:** Metastatic Breast Cancer
- **Phase:** 3
- **Target geography:** United States
- **Total number of sites:** 107

Background

The sponsor was launching a breast cancer trial but, amidst an increasingly congested market, knew a number of competing studies would be kicking off within a similar time frame. In order to avoid competition for their trial, they proactively sought out a solution for identifying a broader range of qualified sites, looking to find ones that they wouldn't typically have access to.

The Problem

The sponsor first came to Inato with major concerns around finding enough experienced sites due to competition in the Metastatic Breast Cancer space. Oncology research is hugely congested and the number of trials is only growing, hitting historic rates with 22% more oncology trial starts occurring in 2022 than 2018. This trend is exacerbated by the concentration of selected sites: the same sites receive the vast majority of trial opportunities, leading to over-saturation of these sites with little capacity left to take on new trials. Before embarking on what would have been a very challenging process, the sponsor wanted to consider alternatives to the standard feasibility and site selection model to deliver results and overcome worries of competition.

Knowing that the volume of competition was out of their control, the sponsor chose to collaborate with Inato to help them find experienced oncology sites who had the scientific interest, capabilities, and staff capacity to conduct this trial. Their team agreed to broaden how they defined a "good site" to ensure a larger volume of sites could be considered. It was also important for the sponsor to prioritize efficiency as they looked for sites capable of activating, screening, and enrolling fast.

---

[1] *Global oncology R&D activity remains high and more patients have been treated for cancer, says IQVIA Institute for Human Data Science*. Business Wire. (2023, May 24).

The Solution

The sponsor came to Inato as the protocol was being finalized so that they could have sufficient time to engage sites on the platform. Their willingness to share key protocol information upfront enabled the study to be launched significantly earlier than previous oncology studies. This timeframe enabled interested sites to make an informed decision about whether or not to move forward with the opportunity.

From start to finish, the process was made with sites in mind. By requiring only standard equipment and experience in oncology, the sponsor connected with many more diverse, highly qualified community-based sites.

Thanks to the broad requirements, more sites than ever before were matched with the trial on Inato's platform. Inato's Site Partnership Managers worked closely with sites that felt this was the right fit for their patients, supporting them through the application to help them showcase their unique attributes and boost their ability to get selected. Using Inato's Enrollment Plan, sites were able to share a comprehensive look into their capabilities, displaying diversity breakdowns, enrollment estimations, and similar trial experience, enabling the sponsor to be confident that they had the ability to perform. With this information, the sponsor found over half of those selected had previously overenrolled in similar trials, and 84% served diverse communities. Ultimately 19 sites were selected through Inato.

Inato sites screened

57% faster

and enrolled

66% faster

than non-Inato sites.

(PER MONTH)



84%

of the selected Inato sites serve diverse communities.

The sponsor's flexibility and early planning removed barriers and limitations, allowing them to find the right sites they needed to combat competition and efficiently kick off the study with Inato. The sponsor has been pleased with the speed at which selected community sites were able to start the study. Seventy-five percent of the Inato sites were activated in less than 6 months and enrollment started soon after, indicating a promising trajectory for this breast cancer trial.

Interested in finding the right sites for your trial?
Reach out today at contact@inato.com